Holocene Advisors LP Has $42.61 Million Stock Holdings in Biohaven Ltd. (NYSE:BHVN)

Holocene Advisors LP decreased its position in shares of Biohaven Ltd. (NYSE:BHVN) by 49.7% in the third quarter, Holdings Channel.com reports. The firm owned 852,627 shares of the company’s stock after selling 843,728 shares during the period. Holocene Advisors LP’s holdings in Biohaven were worth $42,606,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Farallon Capital Management LLC increased its stake in shares of Biohaven by 181.4% during the 2nd quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock worth $78,028,000 after purchasing an additional 1,449,000 shares during the last quarter. Armistice Capital LLC increased its position in Biohaven by 74.8% during the second quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock worth $48,489,000 after buying an additional 597,705 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Biohaven by 563.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company’s stock valued at $25,416,000 after buying an additional 431,954 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Biohaven by 166.8% in the second quarter. American Century Companies Inc. now owns 511,237 shares of the company’s stock worth $17,745,000 after buying an additional 319,634 shares during the last quarter. Finally, ARS Investment Partners LLC boosted its stake in shares of Biohaven by 47.8% during the 2nd quarter. ARS Investment Partners LLC now owns 940,512 shares of the company’s stock worth $32,645,000 after acquiring an additional 304,141 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on BHVN. Jefferies Financial Group started coverage on Biohaven in a report on Monday, September 16th. They issued a “buy” rating and a $57.00 target price for the company. TD Cowen lifted their price target on shares of Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird upped their price objective on shares of Biohaven from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Royal Bank of Canada dropped their target price on shares of Biohaven from $66.00 to $58.00 and set an “outperform” rating on the stock in a report on Monday, November 25th. Finally, Piper Sandler boosted their target price on shares of Biohaven from $66.00 to $76.00 and gave the stock an “overweight” rating in a research report on Monday, September 23rd. Thirteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $62.75.

Biohaven Stock Down 2.8 %

BHVN stock opened at $44.74 on Tuesday. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21. The company has a market cap of $4.52 billion, a PE ratio of -4.79 and a beta of 1.31. The business’s 50-day simple moving average is $49.77 and its 200 day simple moving average is $41.43.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.03). On average, equities research analysts anticipate that Biohaven Ltd. will post -8.85 EPS for the current year.

Insider Buying and Selling at Biohaven

In related news, Director Gregory Bailey acquired 5,000 shares of the stock in a transaction dated Tuesday, September 24th. The shares were bought at an average cost of $44.19 per share, for a total transaction of $220,950.00. Following the purchase, the director now owns 1,620,071 shares in the company, valued at approximately $71,590,937.49. This trade represents a 0.31 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director John W. Childs bought 21,052 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were bought at an average price of $47.50 per share, with a total value of $999,970.00. Following the transaction, the director now directly owns 21,052 shares in the company, valued at $999,970. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 16.00% of the company’s stock.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.